Chugai Starts Phase III Clinical Trial of Actemra for COVID-19 Pneumonia in Japan
Dear Investor, Please find attached a press release by Chugai:https://www.roche.com/200408e-ACT-COVID-19-trial.pdf Do not hesitate to contact us for any further questions. With best regards, (Source: Roche Investor Update)
Source: Roche Investor Update - April 8, 2020 Category: Pharmaceuticals Source Type: news
First Report of MM Patient Treated for COVID-19 With Tocilizumab First Report of MM Patient Treated for COVID-19 With Tocilizumab
Investigators from China reported the first case of COVID-19 in a patient with multiple myeloma who was successfully treated with the humanized anti-IL-6 receptor antibody tocilizumab.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 8, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Second study will assess sarilumab for Covid-19
The Phase II/III trial will evaluate the IL-6 inhibitor in the treatment of Covid-19 patients in Italy, Spain, Germany, France, Japan, Canada and Russia. This is the second trial of its kind, following anecdotal reports that tocilizumab showed efficacy in treating these patients. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 3, 2020 Category: Consumer Health News Source Type: news
Case study: Treating COVID-19 in a patient with multiple myeloma
(American Society of Hematology) A case study of a patient in Wuhan, China, suggests that the immunosuppressant tocilizumab may be an effective COVID-19 treatment for very ill patients who also have multiple myeloma and other blood cancers. The report, published in Blood Advances, also suggests that blood cancer patients may have atypical COVID-19 symptoms. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 3, 2020 Category: Infectious Diseases Source Type: news
FDA Approves Phase III Clinical Trial of Tocilizumab for COVID-19 Pneumonia
The FDA has approved a phase III clinical trial to assess the safety and efficacy of intravenous tocilizumab (Actemra) plus standard of care in hospitalized adult patients with severe COVID-19 pneumonia. (Source: CancerNetwork)
Source: CancerNetwork - March 26, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
